946 related articles for article (PubMed ID: 21866091)
1. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
Tissandié E; Morelle W; Berthelot L; Vrtovsnik F; Daugas E; Walker F; Lebrec D; Trawalé JM; Francoz C; Durand F; Moura IC; Paradis V; Moreau R; Monteiro RC
Kidney Int; 2011 Dec; 80(12):1352-63. PubMed ID: 21866091
[TBL] [Abstract][Full Text] [Related]
2. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
[TBL] [Abstract][Full Text] [Related]
3. Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosis.
Novak J; Julian BA
Kidney Int; 2011 Dec; 80(12):1252-4. PubMed ID: 22126980
[TBL] [Abstract][Full Text] [Related]
4. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.
Papista C; Lechner S; Ben Mkaddem S; LeStang MB; Abbad L; Bex-Coudrat J; Pillebout E; Chemouny JM; Jablonski M; Flamant M; Daugas E; Vrtovsnik F; Yiangou M; Berthelot L; Monteiro RC
Kidney Int; 2015 Aug; 88(2):276-85. PubMed ID: 25807036
[TBL] [Abstract][Full Text] [Related]
5. Role of IgA receptors in the pathogenesis of IgA nephropathy.
Lechner SM; Papista C; Chemouny JM; Berthelot L; Monteiro RC
J Nephrol; 2016 Feb; 29(1):5-11. PubMed ID: 26572664
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.
Cambier A; Gleeson PJ; Abbad L; Canesi F; da Silva J; Bex-Coudrat J; Deschênes G; Boyer O; Rabant M; Ulinski T; Hogan J; Peuchmaur M; Berthelot L; Monteiro RC
Kidney Int; 2022 Feb; 101(2):274-287. PubMed ID: 34756952
[TBL] [Abstract][Full Text] [Related]
7. Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy.
Xu L; Li B; Huang M; Xie K; Li D; Li Y; Gu H; Fang J
PLoS One; 2016; 11(7):e0159426. PubMed ID: 27437939
[TBL] [Abstract][Full Text] [Related]
8. Murine Models of Human IgA Nephropathy.
Suzuki H; Suzuki Y
Semin Nephrol; 2018 Sep; 38(5):513-520. PubMed ID: 30177023
[TBL] [Abstract][Full Text] [Related]
9. New insights in the pathogenesis of IgA nephropathy.
Monteiro RC
Nefrologia; 2005; 25 Suppl 2():82-6. PubMed ID: 16050408
[TBL] [Abstract][Full Text] [Related]
10. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors.
Roccatello D; Picciotto G; Torchio M; Ropolo R; Ferro M; Franceschini R; Quattrocchio G; Cacace G; Coppo R; Sena LM
Lab Invest; 1993 Dec; 69(6):714-23. PubMed ID: 8264233
[TBL] [Abstract][Full Text] [Related]
11. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
12. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
Tamouza H; Chemouny JM; Raskova Kafkova L; Berthelot L; Flamant M; Demion M; Mesnard L; Paubelle E; Walker F; Julian BA; Tissandié E; Tiwari MK; Camara NO; Vrtovsnik F; Benhamou M; Novak J; Monteiro RC; Moura IC
Kidney Int; 2012 Dec; 82(12):1284-96. PubMed ID: 22951891
[TBL] [Abstract][Full Text] [Related]
13. Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy.
van der Boog PJ; De Fijter JW; Van Kooten C; Van Der Holst R; Van Seggelen A; Van Es LA; Daha MR
Kidney Int; 2003 Feb; 63(2):514-21. PubMed ID: 12631116
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
[TBL] [Abstract][Full Text] [Related]
15. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.
Xu LX; Zhao MH
Kidney Int; 2005 Jul; 68(1):167-72. PubMed ID: 15954905
[TBL] [Abstract][Full Text] [Related]
16. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
Ebefors K; Liu P; Lassén E; Elvin J; Candemark E; Levan K; Haraldsson B; Nyström J
BMC Nephrol; 2016 Apr; 17():40. PubMed ID: 27044423
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA.
Grossetête B; Launay P; Lehuen A; Jungers P; Bach JF; Monteiro RC
Kidney Int; 1998 May; 53(5):1321-35. PubMed ID: 9573548
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
19. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
[TBL] [Abstract][Full Text] [Related]
20. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.
Novak J; Tomana M; Matousovic K; Brown R; Hall S; Novak L; Julian BA; Wyatt RJ; Mestecky J
Kidney Int; 2005 Feb; 67(2):504-13. PubMed ID: 15673298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
